Hope Rugo, Professor of Medicine and Director of the Breast Oncology Clinical Trials Program at the University of California at San Francisco, shared a post on X:
“PersevERA: 1st line giredestrant/CDK4/6 inhibitor vs aromatase inhibitor (AI)/CDK4/6 inhibitor failed to meet its primary PFS endpoint (numerical difference but not statistically significant).
So mutant ESR1 (mESR1) key for oral SERDs for endocrine therapy–sensitive metastatic breast cancer (ET-sensitive MBC) but not early-stage breast cancer (ESBC)?
Giredestrant statistically significantly better in 2nd line with everolimus (EVE) and high-risk ESBC. SERENA-4 results will be key.
Understanding biology will be key here clearly given other positive trial results (lidERA and evERA). When is mESR1 required to show superiority of oral SERD over AI? What other biologic factors play a role? More data pending…”
Other articles featuring Hope Rugo on OncoDaily.